CG
KRYS icon

Cynosure Group’s Krystal Biotech KRYS Stock Holding History

Cynosure Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,649
Closed -$426K – 227
2026
Q1 		$426K Sell
1,649
-757
-31% -$201K 0.05% 121
2025
Q4 		$593K Sell
2,406
-3,512
-59% -$739K 0.06% 114
2025
Q3 		$1.04M Hold
5,918
– – 0.11% 70
2025
Q2 		$813K Buy
5,918
+2,016
+52% +$296K 0.09% 115
2025
Q1 		$704K Buy
3,902
+272
+7% +$45.8K 0.1% 105
2024
Q4 		$569K Sell
3,630
-359
-9% -$63.7K 0.09% 123
2024
Q3 		$726K Sell
3,989
-335
-8% -$64.6K 0.11% 116
2024
Q2 		$794K Buy
4,324
+557
+15% +$93.5K 0.13% 99
2024
Q1 		$670K Buy
+3,767
New +$523K 0.12% 99

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cynosure Group's KRYS Position: Q2 2026 in Review

Cynosure Group sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 1,649 shares — an estimated $426K sold.

Cynosure Group first reported a position in KRYS in Q1 2024 and held it in 9 quarters. The position peaked at $1.04M in Q3 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Cynosure Group reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Cynosure Group sold 1,649 Krystal Biotech shares in Q2 2026, an estimated $426K.
  • Cynosure Group first reported a position in Krystal Biotech in Q1 2024 and held it in 9 quarters.
  • Cynosure Group's Krystal Biotech position peaked at $1.04M in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Cynosure Group's 13F filing for Q2 2026, filed 5 Aug 2026.